Medicamen Organics Past Earnings Performance
Past criteria checks 4/6
Medicamen Organics has been growing earnings at an average annual rate of 69.8%, while the Pharmaceuticals industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 0.8% per year. Medicamen Organics's return on equity is 15.8%, and it has net margins of 9.5%.
Key information
69.8%
Earnings growth rate
65.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 0.8% |
| Return on equity | 15.8% |
| Net Margin | 9.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Medicamen Organics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 253 | 24 | 34 | 0 |
| 31 Mar 23 | 221 | 10 | 33 | 0 |
| 31 Mar 22 | 210 | 1 | 29 | 0 |
| 31 Mar 21 | 250 | 2 | 28 | 0 |
| 31 Mar 20 | 315 | 1 | 30 | 0 |
Quality Earnings: MEDIORG has a high level of non-cash earnings.
Growing Profit Margin: MEDIORG's current net profit margins (9.5%) are higher than last year (4.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MEDIORG's earnings have grown significantly by 69.8% per year over the past 5 years.
Accelerating Growth: MEDIORG's earnings growth over the past year (148%) exceeds its 5-year average (69.8% per year).
Earnings vs Industry: MEDIORG earnings growth over the past year (148%) exceeded the Pharmaceuticals industry 18.2%.
Return on Equity
High ROE: MEDIORG's Return on Equity (15.8%) is considered low.